Biocryst Pharmaceuticals Inc (BCRX)
R&D Expense Growth
-13.84%
Quarterly · Period ending:
BCRX R&D Expense Growth
Latest reported-13.84%period ending
Latest reported-13.84%period ending
BCRX Quarterly R&D Growth (QoQ) (0.00% → -13.84%)
Latest values, visible window
High-resolution chart · PNG
BCRX r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| -13.8431% | |
| 46.3982% | |
| -6.926% | |
| 2.0329% | |
| 16.41% | |
| -24.6172% | |
| 20.35% | |
| 9.1912% | |
| -19.0781% | |
| -33.6307% | |
| 49.4315% | |
| -8.5234% | |
| 5.9085% | |
| -33.9025% | |
| 38.8074% | |
| -14.9218% | |
| -5.1561% | |
| 2.8821% | |
| 27.1317% | |
| -5.4886% | |
| 24.5976% | |
| 20.0289% | |
| 16.892% | |
| 9.9898% | |
| -7.9318% | |
| 11.5523% | |
| 6.5844% | |
| -9.2518% | |
| 0.6838% | |
| 17.336% | |
| 6.4755% | |
| 4.7406% | |
| 13.9309% | |
| 8.9636% | |
| -3.3411% | |
| 11.1048% | |
| -6.0286% | |
| 37.9339% | |
| -13.8036% | |
| -0.4306% | |
| -31.1628% | |
| 8.0433% | |
| -5.083% | |
| 21.4415% | |
| -3.4813% | |
| -7.5095% | |
| 41.9914% | |
| 17.7916% | |
| 20.5162% | |
| -41.1874% | |
| 95.7377% | |
| -31.9833% | |
| 58.2512% | |
| -33.174% | |
| -8.1345% | |
| -5.5177% | |
| -17.2528% | |
| 1.5121% | |
| 2.9718% | |
| 5.703% | |
| 8.0653% | |
| -45.2545% | |
| 23.0505% | |
| 30.264% | |
| -40.8556% | |
| -21.1947% | |
| 73.9093% | |
| 62.1422% | |
| -0.6732% | |
| -48.8251% | |
| 37.9072% | |
| 19.6141% | |
| -38.9305% | |
| -24.7853% | |
| -2.072% | |
| 56.3667% | |
| 17.4004% | |
| 44.6063% | |
| -32.7365% | |
| 48.7936% | |
| 39.1272% | |
| 33.1539% | |
| -15.6843% | |
| 36.1201% | |
| 1.7005% | |
| 10.1038% | |
| -2.8501% | |
| 11.2695% | |
| -12.7433% | |
| 68.1741% | |
| -4.5733% | |
| 4.7218% | |
| 19.1241% | |
| -1.9496% | |
| -19.9719% | |
| -27.5303% | |
| -18.7488% | |
| 7.3523% | |
| 77.3165% | |
| 4.2741% |